Genetic Variants of ABCA1 Modify Alzheimer Disease Risk and Quantitative Traits Related to β-Amylolid Metabolism

Human Mutation

Volumn 23, Issue 4, 2004, Pages 358-367

  Katzov, Hagit ^a   Chalmers, Katy ^b   Palmgren, Juni ^a,c   Andreasen, Niels ^d   Johansson, Boo ^e   Cairns, Nigel J ^f   Gatz, Margaret ^g   Wilcock, Gordon K ^b   Love, Seth ^b   Pedersen, Nancy L ^a,g   Brookes, Anthony J ^a   Blennow, Kaj ^h   Kehoe, Patrick G ^b   Prince, Jonathan A ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ABCA1; AD; Alzheimer disease; Amyloid beta; Amyloidosis; APP; Haplotype; SNP

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; AMYLOID BETA PROTEIN[1-42]; UNCLASSIFIED DRUG;

ABCA1 GENE; ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; CEREBROSPINAL FLUID ANALYSIS; CHOLESTEROL METABOLISM; CHROMOSOME 9Q; GENE LOCUS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; NUCLEOTIDE SEQUENCE; POPULATION GENETICS; PRIORITY JOURNAL; PROTEIN METABOLISM; QUANTITATIVE TRAIT;

EID: 11144357626     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.20012     Document Type: Article

References (45)

1. Alafuzoff I, Iqbal K, Fridén H, Adolfsson R, Winblad B. 1987. Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol 74:209-225.
2. Andreasen N, Hesse C, Davidsson P, Wallin A, Minthon L, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K. 1999. Cerebrospinal fluid b-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56:673-680.
3. Andreasen N, Blennow K. 2002. beta-Amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer disease. Peptides 23:1205-1214.
4. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S, McInnis MG, Go RC, Vekrellis K, Selkoe DJ, Saunders AJ, Tanzi RE. 2000. Evidence for genetic linkage of Alzheimer disease to chromosome 10q. Science 290:2302-2303.
5. Bertram L, Tanzi RE. 2001. Of replications and refutations: the status of Alzheimer disease genetic research. Curr Neurol Neurosci Rep 1:442-450.
6. Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener H, Perry RT, Collins JS, Harrell LE, Go RC, Mahoney A, Beaty T, Fallin MD, Avramopoulos D, Chase GA, Folstein MF, McInnis MG, Bassett SS, Doheny KJ, Pugh EW, Tanzi R. 2003. Results of a high-resolution genome screen of 437 Alzheimer disease families. Hum Mol Genet 12:23-32.
7. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. 1995. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26:231-245.
8. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W, Barlage S, Buchler C, Porsch-Ozcurumez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G. 1999. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 22:347-351.
9. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop B, Pimstone S, Kastelein JJ, Hayden MR. 1999. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 22:336-345.
10. Chalmers K, Wilcock GK, Love S. 2003. APOE ε4 influences the pathological phenotype of Alzheimer disease by favouring cerebrovascular over parenchymal accumulation of Aβ protein. Neuropathol Appl Neurobiol 29:231-238.
11. Clee SM, Zwinderman AH, Engert JC, Zwarts KY, Molhuizen HO, Roomp K, Jukema JW, van Wijland M, van Dam M, Hudson TJ, Brooks-Wilson A, Genest J Jr, Kastelein JJ, Hayden MR. 2001. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation 103:1198-1205.
12. Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M, Adamson J, Ronald J, Blangero J, Hutton M, Younkin SG. 2000. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer disease pedigrees. Science 290:2303-2304.
13. Excoffier L, Slatkin M. 1995. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 12:921-927.
14. Feuk L, Prince JA, Blennow K, Brookes AJ. 2003. Further evidence for role of a promoter variant in the TNFRSF6 gene in Alzheimer disease. Hum Mutat 21:53-60.
15. Fratiglioni L, De Ronchi D, Aguero-Torres H. 1999. Worldwide prevalence and incidence of dementia. Drugs Aging 15:365-375.
16. Galasko D. 1998. Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer disease. J Neural Transm Suppl 53:209-221.
17. Gatz M, Pedersen NL, Berg S, Johansson B, Johansson K, Mortimer JA, Posner SF, Viitanen M, Winblad B, Ahlbom A. 1997. Heritability for Alzheimer disease: the study of dementia in Swedish twins. J Gerontol A Biol Sci Med Sci 52:117-125.
18. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J. 1991. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer disease. Nature 349:704-706.
19. Hill WG. 1974. Estimation of linkage disequilibrium in randomly mating populations. Heredity 33:229-239.
20. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van Duijn CN, Van Broeckhoven C, Grobbee DE. 1997. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer disease in the Rotterdam Study. Lancet 349:151-154.
21. Hong HS, Rhyne J, Zeller K, Miller M. 2002. Novel ABCA1 compound variant associated with HDL cholesterol deficiency. Biochim Biophys Acta 1587:60-64.
22. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. 2000. Statins and the risk of dementia. Lancet 356:1627-1631.
23. Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, Di Genova G, Ueda H, Cordell HJ, Eaves IA, Dudbridge F, Twells RC, Payne F, Hughes, W, Nutland S, Stevens H, Carr P, Tuomilehto-Wolf E, Tuomilehto J, Gough SC, Clayton DG, Todd JA. 2001. Haplotype tagging for the identification of common disease genes. Nat Genet 29:233-237.
24. Kehoe P, Wavrant-De Vrieze F, Crook R, Wu WS, Holmans P, Fenton I, Spurlock G, Norton N, Williams H, Williams N, Lovestone S, Perez-Tur J, Hutton M, Chartier-Harlin MC, Shears S, Roehl K, Booth J, Van Voorst W, Ramic D, Williams J, Goate A, Hardy J, Owen MJ. 1999a. A full genome scan for late onset Alzheimer disease. Hum Mol Genet 8:237-245.
25. Kehoe PG, Russ C, McIlory S, Williams H, Holmans P, Holmes C, Liolitsa D, Vahidassr D, Powell J, McGleenon B, Liddell M, Plomin R, Dynan K, Williams N, Neal J, Cairns NJ, Wilcock G, Passmore P, Lovestone S, Williams J, Owen MJ. 1999b. Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat Genet 21:71-72.
26. Kehoe PG, Katzov H, Bennet A, Johansson B, Wiman B, Cairns N, Wilcock GK, Brookes AJ, Blennow K, Prince JA. 2003. Haplotypes extending across ACE are associated with Alzheimer disease. Hum Mol Gen 12:859-867.
27. Koldamova RP, Lefterov IM, Ikonomovic MD, Skoko J, Lefterov PI, Isanski BA, DeKosky ST, Lazo JS. 2003. 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter Al expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol Chem 278:13244-13256.
28. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D, Roher AE. 1998. Elevated low-density lipoprotein in Alzheimer disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun 252:711-715.
29. Merched A, Xia Y, Visvikis S, Serot JM, Siest G. 2000. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer disease Neurobiol Aging 21:27-30.
30. Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, Shears S, Booth J, DeVrieze FW, Crook R, Hamshere M, Abraham R, Tunstall N, Rice F, Carty S, Lillystone S, Kehoe P, Rudrasingham V, Jones L, Lovestone S, Perez-Tur J, Williams J, Owen MJ, Hardy J, Goate AM. 2000. Susceptibility locus for Alzheimer disease on chromosome 10. Science 290:2304-2305.
31. Niu T, Qin ZS, Xu X, Liu JS. 2002. Bayesian haplotype inference for multiple linked single-nucleotide polymorphisms. Am J Hum Genet 70:157-169.
32. Oram JF, Lawn RM. 2001. ABCA1 the gatekeeper for eliminating excess tissue cholesterol. J Lipid Res 42:1173-1179.
33. Prince JA, Feuk L, Howell WM, Jobs M, Emahazion T, Blennow K, Brookes AJ. 2001. Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): design criteria and assay validation. Genome Res 11:152-162.
34. Prince JA, Feuk L, Gu HF, Johansson B, Gatz M, Blennow K, Brookes AJ. 2003. Genetic variation in a haplotype block spanning IDE influences Alzheimer disease. Hum Mutat 22:363-371.
35. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman KT. 1995. Familial Alzheimer disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer disease type 3 gene. Nature 376:775-758.
36. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denefle P, Assmann G. 1999. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 22:352-355.
37. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, Da Silva HAR, Haines JL, Pericak-Vance MA, Tanzi RE, Roses AD, Fraser PE, Rommens M, St George-Hyslop PH. 1995. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer disease. Nature 375:754-760.
38. Sparks DL, Scheff SW, Hunsaker JC III, Liu H, Landers T, Gross DR. 1994. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126:88-94.
39. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD. 1993. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:8098-8102.
40. Strozyk D, Blennow K, White LR, Launer LJ. 2003. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60:652-656.
41. Tishkoff SA, Pakstis AJ, Ruano G, Kidd KK. 2000. The accuracy of statistical methods for estimation of haplotype frequencies: an example from the CD4 locus. Am J Hum Genet 67:518-522.
42. Wollmer MA, Streffer JR, Lutjohann D, Tsolaki M, Iakovidou V, Hegi T, Pasch T, Jung HH, Bergmann K, Nitsch RM, Hock C, Papassotiropoulos A. 2003. ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer disease. Neurobiol Aging 24:421-426.
43. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. 2000. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57:1439-1443.
44. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. 1985. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27:335-371.
45. Zwarts KY, Clee SM, Zwinderman AH, Engert JC, Singaraja R, Loubser O, James E, Roomp K, Hudson TJ, Jukema JW, Kastelein JJ, Hayden MR. 2002. ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. Clin Genet 61:115-125.